Return On Equity of Inhibitor Therapeutics, Inc. from 30 Jun 2014 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Inhibitor Therapeutics, Inc. quarterly and annual Return On Equity in % history and change rate from 30 Jun 2014 to 30 Sep 2025.
  • Inhibitor Therapeutics, Inc. Return On Equity for the quarter ending 30 Sep 2025 was -338%, a 378% decline year-over-year.
  • Inhibitor Therapeutics, Inc. annual Return On Equity for 2024 was -94%, a 107% decline from 2023.
  • Inhibitor Therapeutics, Inc. annual Return On Equity for 2023 was -45%, a 97% increase from 2022.
  • Inhibitor Therapeutics, Inc. annual Return On Equity for 2022 was -1427%, a 16907% decline from 2021.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Change (%)
Return On Equity, Annual (%)
Return On Equity, YoY Annual Change (%)

Inhibitor Therapeutics, Inc. Quarterly Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
Q3 2025 -338% -267% -378% 01 Jul 2025 30 Sep 2025
Q2 2025 -185% -126% -214% 01 Apr 2025 30 Jun 2025
Q1 2025 -121% -67% -124% 01 Jan 2025 31 Mar 2025
Q4 2024 -94% -49% -107% 01 Oct 2024 31 Dec 2024
Q3 2024 -71% -212% -150% 01 Jul 2024 30 Sep 2024
Q2 2024 -59% -291% -125% 01 Apr 2024 30 Jun 2024
Q1 2024 -54% -628% -109% 01 Jan 2024 31 Mar 2024
Q4 2023 -45% +1381% +97% 01 Oct 2023 31 Dec 2023
Q3 2023 142% +134% +1787% 01 Jul 2023 30 Sep 2023
Q2 2023 232% +224% +2955% 01 Apr 2023 30 Jun 2023
Q1 2023 574% +566% +7581% 01 Jan 2023 31 Mar 2023
Q4 2022 -1427% -1435% -16907% 01 Oct 2022 31 Dec 2022
Q3 2022 7.5% -1.8% -19% 01 Jul 2022 30 Sep 2022
Q2 2022 7.6% -8.6% -53% 01 Apr 2022 30 Jun 2022
Q1 2022 7.5% -16% -69% 01 Jan 2022 31 Mar 2022
Q4 2021 8.5% -24% -74% 01 Oct 2021 31 Dec 2021
Q3 2021 9.3% -45% -83% 01 Jul 2021 30 Sep 2021
Q2 2021 16% -60% -79% 01 Apr 2021 30 Jun 2021
Q1 2021 24% -85% -78% 01 Jan 2021 31 Mar 2021
Q4 2020 33% -145% -82% 01 Oct 2020 31 Dec 2020
Q3 2020 54% -328% -86% 01 Jul 2020 30 Sep 2020
Q2 2020 76% -281% -79% 01 Apr 2020 30 Jun 2020
Q1 2020 109% -234% -68% 01 Jan 2020 31 Mar 2020
Q4 2019 178% -179% -50% 01 Oct 2019 31 Dec 2019
Q3 2019 382% +50% +15% 01 Jul 2019 30 Sep 2019
Q2 2019 357% -818% -70% 01 Apr 2019 30 Jun 2019
Q1 2019 343% +997% 01 Jan 2019 31 Mar 2019
Q4 2018 356% +740% 01 Oct 2018 31 Dec 2018
Q3 2018 332% +560% 01 Jul 2018 30 Sep 2018
Q2 2018 1175% +1395% 01 Apr 2018 30 Jun 2018
Q1 2018 -654% -453% -225% 01 Jan 2018 31 Mar 2018
Q4 2017 -383% -189% -97% 01 Oct 2017 31 Dec 2017
Q3 2017 -228% +43% +16% 01 Jul 2017 30 Sep 2017
Q2 2017 -220% +132% +37% 01 Apr 2017 30 Jun 2017
Q1 2017 -201% +383% +66% 01 Jan 2017 31 Mar 2017
Q4 2016 -194% +376% +66% 01 Oct 2016 31 Dec 2016
Q3 2016 -271% +363% +57% 01 Jul 2016 30 Sep 2016
Q2 2016 -352% +614% +64% 01 Apr 2016 30 Jun 2016
Q1 2016 -585% -4056% -117% 01 Jan 2016 31 Mar 2016
Q4 2015 -570% -2066% -138% 01 Oct 2015 31 Dec 2015
Q3 2015 -634% -1330% -191% 01 Jul 2015 30 Sep 2015
Q2 2015 -966% -1598% -253% 01 Apr 2015 30 Jun 2015
Q1 2015 3472% 01 Jan 2015 31 Mar 2015
Q4 2014 1496% 01 Oct 2014 31 Dec 2014
Q3 2014 696% 01 Jul 2014 30 Sep 2014
Q2 2014 632% 01 Apr 2014 30 Jun 2014

Inhibitor Therapeutics, Inc. Annual Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
2024 -94% -49% -107% 01 Jan 2024 31 Dec 2024
2023 -45% +1381% +97% 01 Jan 2023 31 Dec 2023
2022 -1427% -1435% -16907% 01 Jan 2022 31 Dec 2022
2021 8.5% -24% -74% 01 Jan 2021 31 Dec 2021
2020 33% -145% -82% 01 Jan 2020 31 Dec 2020
2019 178% -179% -50% 01 Jan 2019 31 Dec 2019
2018 356% +740% 01 Jan 2018 31 Dec 2018
2017 -383% -189% -97% 01 Jan 2017 31 Dec 2017
2016 -194% +376% +66% 01 Jan 2016 31 Dec 2016
2015 -570% -2066% -138% 01 Jan 2015 31 Dec 2015
2014 1496% 01 Jan 2014 31 Dec 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.